At Ostia Sciences, we’ve discovered a new type of natural antimicrobial peptides by friendly bacteria found in 1-2% of humans within their oral cavity. The first of these antimicrobials is called Salivaricin 10, and it’s the world’s first patented phosphorylated lantibiotic—a special class of antimicrobial peptides.
Salivaricin 10 is a game-changer in the fight against harmful bacteria. Its unique structure allows it to target these pathogens without disturbing the beneficial bacteria in your body. By naturally coexisting with the bacteria in your mouth, it becomes a powerful ally in fighting infections and keeping your immune system strong and free from inflammation. In short, Salivaricin 10 is your body’s partner in the battle against harmful germs, without disrupting the balance of beneficial bacteria.
At Ostia Sciences, we are driven by the belief that everyone should have access to this potent natural defense. By making Salivaricin 10 available to a wider population, we envision a future where oral and respiratory health is significantly improved, infections are prevented, and the risk of disease is reduced. All this, while maintaining the delicate balance of good bacteria in your body.
Our team has extensive expertise in comparative genomics. We use advanced technologies like Single Molecule, Real-Time (SMRT) sequencing for comprehensive whole-genome sequencing of our bacterial strains. This allows us to identify antibiotic resistance, virulence factors, and other crucial genes, ensuring our strains are safe and free from antibiotic-resistant elements. Additionally, our genome mining platform detects beneficial genes that enable probiotic bacteria to produce novel metabolites to combat pathogens.
Most commercially available probiotics for oral and respiratory health can’t effectively colonize or adhere to human tissues because they lack essential adhesion proteins. We have developed new artificial models to ensure that our strains can successfully colonize the human body and deliver their beneficial effects.
Bio-fermentation is a process where bacteria consume nutrients to grow and produce beneficial natural products. We partner with leading probiotic manufacturing facilities to optimize this process and ensure the quality, purity, and effectiveness of our probiotics.
We collaborate with leading academic research institutes and prominent primary investigators to validate our thoughtfully designed probiotic formulations through double-blind, randomized, placebo-controlled clinical trials. Initially, our in vitro (preclinical) data help us ensure the safety of our probiotic strains and identify their ability to produce novel beneficial molecules, which are tested against a range of pathogens. For certain health indications, we also collect animal data to discover new endpoints and benefits for the human microbiome.
We have developed an innovative multispecies biofilm model that replicates the complex biofilms found in the human oral cavity. Since most oral bacteria within the human microbiome exist as intricate multispecies biofilms, our new model allows for robust screening and testing of biotherapeutics and probiotics. This ensures that our products can effectively modulate bacterial communities not only in liquid environments but also within these challenging multispecies biofilms, enhancing their potential for oral health applications.
Our goal is to develop beneficial microbes from the human oral microbiome, human breast milk, and fermented food, which are known to be rich sources of natural products with a range of biological activities.
Our research programs fuel product innovation across multiple categories to support the development and maturation of the human microbiome from birth through all stages of life